Close Menu

Waters

Waters posted revenues of $464.9 million for the quarter as the SARS-CoV-2 pandemic drove a drop in sales globally, including a 45 percent decline in China.

Revenues during the quarter were $716.3 million, beating Wall Street estimates, while full year 2019 revenues totaled $2.41 billion.

Highlights included mass spec-focused developments like data-independent acquisition and ion mobility along with platforms including Thermo Fisher's Q Exactive.

With new instruments and workflows able to quantify thousands of proteins in as little as five minutes, 2019 was the year proteomics cracked its throughput problem.

Waters posted revenues of $577.3 million, short of the average Wall Street estimate of $588.9 million, as soft US pharma sales negatively impacted businesses.

Though Meehan was cautious on Waters in the near term, he provided a favorable outlook on Thermo Fisher Scientific.

The Swiss company markets the WAVE system, a waveguide interferometry-based instrument for studying molecular interactions in real time.

More powerful and user-friendly mass spec systems could drive an uptick in interest in the technique, suggested a leading top-down researcher.

The company's Q2 revenues were up less than 1 percent from $596.2 million in Q2 2018, and short of the average Wall Street estimate of $601.4 million.

The new partnership will support the analysis of glycans in 30,000 human samples by the end of 2021.

Pages

Nobel laureates and scientific societies urge NIH and the Department of Health and Human Services to revisit the recent decision to end funding for a coronavirus grant.

Bloomberg reports that BGI's SARS-CoV-2 testing sites in the Middle East have raised concerns among US officials.

A new Pew Research Center poll finds confidence in medical researchers has grown among US adults since the start of the coronavirus pandemic.

In Science this week: machine learning algorithm for faster Mendelian disorder diagnoses, gene linked to safe response to nitrogen-containing bisphosphonates, and more.